News

Deal Announcements

BioRelix Records Venture Capital Debt Investment

Friday, March 23, 2012 5:30:00 AM PDT | VentureDeal Staff
   New Haven, Connecticut  --  Biotechnology company BioRelix has received $2.5 million in venture capital debt, according to an SEC regulatory filing.

BioRelix is developing antibiotics that target pathogens resistant to currently available drugs.

Investors in the financing were not disclosed, was how the company intends to use the funding proceeds.

BioRelix is backed by a large syndicate of venture capital and corporate investors.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1